Melanotan II and PT-141 are both melanocortin peptides, with Melanotan II acting as an MC4R agonist, primarily explored for its potential in inducing tanning to prevent UV damage and as an adjunct for vitiligo repigmentation. Evidence also suggests its potential in obesity treatment, particularly for genetic forms. PT-141, also known as bremelanotide, is primarily indicated for treating sexual dysfunction, specifically low sexual desire in premenopausal women, demonstrating efficacy in improving satisfying sexual events and overall sexual function. Both peptides modulate the melanocortin system but are directed towards different therapeutic applications based on the studies indexed here.
| Melanotan II | PT-141 | |
|---|---|---|
| Drug class | melanocortin agonist | melanocortin agonist |
| Studies in corpus | 80 | 72 |
| Highest evidence tier | meta analysis | meta analysis |
| Evidence tier mix | other · 12 case report · 11 preclinical animal · 45 meta analysis · 1 in vitro · 6 review · 4 rct · 1 | other · 13 cohort · 1 rct · 9 review · 34 preclinical animal · 4 case report · 2 meta analysis · 2 in vitro · 3 |
| Studies with explicit sample size | 4 | 4 |
| Head-to-head studies in corpus | 3 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Melanotan II and PT-141 batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 805 Melanotan II batches across 465 manufacturers, 99.63% avg purity.
We tested 673 PT-141 batches across 382 manufacturers, 99.71% avg purity.
We hold deeper lab coverage on Melanotan II (805 batches tested). PT-141 edges ahead on average measured purity (99.63% vs 99.71%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Studies in our corpus that mention both Melanotan II and PT-141 — the gold-standard direct comparison evidence.
This case report underscores the significant and potentially life-threatening risks associated with the use of unregulated substances like Melanotan II. It highlights that severe adverse events, such as rhabdomyolysis and acute kidney injury, are critical c…
This research highlights the significant therapeutic potential of melanocortin peptides in addressing unmet medical needs. The development of MTI could offer a novel, preventative approach to skin cancer through induced tanning, potentially reducing UV dama…
This research highlights the critical role of advanced analytical techniques in combating the illegal trade of unapproved drugs, which often pose significant health risks to users. The successful identification of melanotan II and bremelanotide in black mar…
No direct head-to-head trials in our corpus. Indirect comparison only. While both are melanocortin peptides, Melanotan II has been linked to significant safety concerns, including severe systemic toxicity, rhabdomyolysis, acute kidney injury, rapid development of atypical moles, and oral mucosa changes, based on case reports. Its use is often associated with unregulated black market products. PT-141, or bremelanotide, has been studied in randomized controlled trials for female sexual dysfunction, showing a dose-dependent response and demonstrating safety and efficacy in improving sexual desire and function in premenopausal women. The evidence tier for PT-141 includes multiple RCTs, whereas much of the information on Melanotan II's adverse effects comes from case reports and analyses of illicit substances.
Looking for vendor-level purity, endotoxin, and HPLC data on Melanotan II or PT-141? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.